Through new partnerships with industry leaders, Nvidia aims to help advance practical use cases for AI in healthcare and life ...

Gene Mack, Gain Therapeutics CEO, provides a look into the future of the company and the use of physics-based artificial ...

Recursion Pharmaceuticals struggles with validation of REC-994 and competition in oncology. Read why RXRX stock is a hold ...

An interdisciplinary research team from Leipzig University and the Saxon AI center ScaDS.AI has developed a novel approach ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) had soared by 15.8% as of 12:06 p.m. ET on Friday. Instead, the stock's ...

Relay Therapeutics' financial stability is strong, but zero Q3 2024 revenue and rising net losses raise concerns. Find out ...

There exists no ‘amyloid cabal’” in Alzheimer’s research, neurologist Dennis Selkoe writes in response to Charles Piller’s “Doctored.” ...

Tokyo, Japan and Cambridge, UK, 14 February 2025 - Nxera Pharma Co., Ltd. ("Nxera” or "the Company”; TSE 4565) provides an ...

Organoids were cultured from healthy donor iPSC sources and differentiated using the human iPSC-derived Cerebral Organoid ...

Stavros Papadopoulos, founder and CEO of TileDB, spoke with Pharmaceutical Executive about how modern databases are struggling to handle life sciences data, which in turn limits scientific discovery.

Investors know the biotech industry is a waiting game—smaller companies in this space often work to secure the funding to ...